Abstract
Part of a three volume series.
Over one billion people suffer from fungal infections worldwide. Although
athlete' s foot, dandruff, vaginal yeast infection and fungal nail are the most
common, there has been a steady increase in the incidence of more serious
infections. This is partially due to the widespread use of antibiotics, which
eliminate or decrease fungi-killing bacteria. Another has been the increased
number of individuals with reduced immune responses caused by AIDS or the
effects of chemotherapy. These are part of the factors that have lead to
nearly 6-billion dollar antifungal drug industry.
Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive
review of the market for anti fungal drugs. This is the first volume of
Kalorama Information' s 2nd edition of its popular three-part series on
anti-infective markets. The report focuses on two segments of antifungal
treatment: systemic and topical. The report covers both currently marketed and
late stage development antifungal products in detail.
For both the systemic and topical antifungal markets, this report includes:
- U.S. and World Revenues
- Forecasts to 2011.
- Overview and Incidence Data
- Description of Products on the Market
- Review of Products in Development
- Competitive Analysis of Leading Providers.
- 10 Key Issues and Trends facing the antifungal industry
Revenues for each segment were generated using dollar and unit sales for each
product. All market data pertain to the world market at the manufacturers'
level. Revenues and market share of major brands such as Lamisil, Diflucan,
Sporanox, Cancidas, Vfend, and others are included.
Competitive analysis is provided for the year 2006. The forecasted market
analysis for 2004-2011 was based on probability of approval and sales of
products in late stage development, product marketing, and demographic trends.
As part of Kalorama' s trusted information-gathering process, the information
for this report was gathered using both primary and secondary research
including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information and developing forecasts.
For the purpose of this study Kalorama Information conducted interviews with
key industry officials, consultants, health care providers, and government
personnel. These sources were the primary basis in gathering information
specifically relating to revenue and market share data presented in this
report. Specific interviews with pharmaceutical company representatives
included marketing directors, division managers, and product representatives.
View Cart
